
Expres²ion files joint-patent on the production of an improved malaria vaccine with the Walter and Eliza Hall Institute of Medical Research

Horsholm, Denmark, April 6, 2017 – Today, Expres²ion Biotech Holding AB (“Expres²ion”), announces that the fully owned subsidiary Expres²ion Biotechnologies ApS has filed a joint patent application for an improved blood-stage malaria vaccine together with the Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia. This patent positions Expres²ion and the Walter and Eliza Hall Institute well for future development of this promising vaccine, addressing a large market with unmet needs. Under a joint vaccine development and patent sharing agreement between Expres²ion and The Walter and Eliza Hall Institute, the parties co-own the joint-patent equally.

Collaboration

The basis of the collaboration and patent filing is the significant advances Expres²ion and the Walter and Eliza Hall Institute have made in the production and development of a novel and improved blood-stage malaria vaccine. It is expected that future development of the vaccine will be funded through grants, with the aim of having a vaccine candidate ready for clinical trials in 2018. The patent application has been filed with the Australian patent office, and if approved, the patent is valid until 2037. Under a joint vaccine development and patent sharing agreement between Expres²ion and The Walter and Eliza Hall Institute, the parties co-own the joint-patent equally.

Despite the urgent medical need for an effective malaria vaccine, no vaccine has yet achieved satisfactory protection against the disease. In a malaria market assessment study by the Boston Consulting Group sponsored by the Malaria Vaccine Initiative, the malaria vaccine demand was estimated to be translated into a global market value of up to \$400M per year.

About the Walter and Eliza Hall Institute

The Walter and Eliza Hall Institute is the oldest research institute in Australia and celebrated its centenary in 2015. Their affiliation with The Royal Melbourne Hospital links research outcomes with clinical practice to accelerate discoveries for health and disease. More than 100 clinical trials based on discoveries made at the Institute are underway. These include trials of vaccines for type 1 diabetes, coeliac disease and malaria, and trials of a new class of anti-cancer agents for treating people with leukaemia and other cancers. More information can be found at website www.wehi.edu.au.

Steen Klysner, CEO, Expres²ion, comments

“We are very pleased with our collaboration with the Walter and Eliza Hall Institute, a very renowned institution in the malaria field. As a consequence, we welcome this opportunity to strengthen our ownership in one of the most promising malaria vaccines currently under development.”

Certified Advisor

Sedermera Fondkommission is appointed as Certified Adviser for Expres²ion.

For further information, please contact:

Steen Klysner, CEO
Telephone: +45 2062 9908
E-mail: sk@expres2ionbio.com

This information is information that Expres²ion is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on April 6, 2017.

About ExpreS²ion

ExpreS²ion Biotech Holding AB, with company register number 559033-3729, has through the wholly owned Danish subsidiary ExpreS²ion Biotechnologies ApS, developed a platform technology enabling cost effective and robust production of complex proteins for the development of vaccines and diagnostics for e.g. Malaria and Zika. Since foundation in 2010, the subsidiary has used its patented ExpreS² platform to produce more than 200 proteins in collaboration with research institutions and biopharmaceutical companies, with an efficiency and success rate superior to competing technologies.